Eighteen-month real-world outcomes of intravitreal aflibercept 8 mg in treatment-naïve neovascular age-related macular degeneration: a UK single-centre experience.
PURPOSE Intravitreal aflibercept 8 mg was developed to extend treatment intervals and reduce injection burden in neovascular age-related macular degeneration (nAMD). We evaluated visual, anatomical, and durability outcomes over 18 months in routine clinical practice. METHODS This retrospective observational study inc...